Enhanced Interferon-β Response Contributes to Eosinophilic Chronic Rhinosinusitis

Area of Science:

• Immunology
• Otorhinolaryngology
• Molecular Biology

Background:

• Type I interferons (IFN-I) are known for antiviral functions and have been linked to eosinophilic inflammation.
• The specific role of IFN-I in the pathogenesis of eosinophilic chronic rhinosinusitis (ECRS) requires further investigation.

Purpose of the Study:

• To investigate the role of Type I interferon (IFN-I) in the development of eosinophilic chronic rhinosinusitis (ECRS).
• To examine the expression and localization of IFN-I components in sinonasal tissues of ECRS patients.
• To assess the impact of IFN-I signaling on key inflammatory mediators in ECRS.

Main Methods:

• Quantitative real-time PCR, ELISA, and immunohistochemistry were used to analyze sinonasal tissues from ECRS patients and controls.
• Murine models of ECRS were established in wild-type and IFNAR1 knockout mice challenged with Aspergillus protease and ovalbumin.
• In vitro studies involved stimulating nasal polyp stromal cells with exogenous IFN-β to measure CCL11 production and downstream signaling.

Main Results:

• ECRS tissues showed significantly higher expression of IFN-β, IL-5, IL-13, and CCL11 compared to controls, with IFN-β colocalizing with CD11c+ cells.
• IFN-β levels positively correlated with eosinophil counts, disease severity (CT score), and other inflammatory markers in ECRS patients.
• IFNAR1 knockout mice exhibited reduced ECRS severity and lower levels of key inflammatory cytokines and chemokines compared to wild-type mice.

Conclusions:

• The Type I interferon (IFN-I) response, specifically IFN-β, is upregulated in eosinophilic chronic rhinosinusitis (ECRS).
• IFN-β signaling appears to play a significant role in ECRS pathogenesis, potentially by enhancing CCL11 production.
• Targeting IFN-β pathways may offer a therapeutic strategy for managing ECRS.